Title: HUMAN PELLINO POLYPEPTIDES

Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
# INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

<table>
<thead>
<tr>
<th>IPC(7)</th>
<th>US CL.</th>
</tr>
</thead>
<tbody>
<tr>
<td>G01N 33/53; C12Q 1/68; C07K 14/52</td>
<td>435/7.1, 6; 530/351, 358</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC.

**B. FIELDS SEARCHED**

<table>
<thead>
<tr>
<th>Minimum documentation searched</th>
<th>Documentation searched other than minimum documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>classification system followed by classification symbols</td>
<td>to the extent that such documents are included in the fields searched</td>
</tr>
</tbody>
</table>

| U.S. | 435/7.1, 6; 530/351, 358 |

Electronic database consulted during the international search (name of database and, where practicable, search terms used):

GenBank, N-Geneseq, A-Geneseq, EMBL, SPTREMBL, IssuedAA, IssuedNA, PIR, Swiss-Port, EAST, STN/Medline

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 01/83739 A2 (IMMUNEX CORPORATION) 08 November 2001 (08.11.2001), especially pages 2-6.</td>
<td>1-7</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

- * \( ^* \) Special categories of cited documents:
  - \( ^* \) later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - \( ^* \) document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - \( ^* \) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - \( ^* \) document of the same patent family

**Date of the actual completion of the international search**

02 July 2004 (02.07.2004)

**Date of mailing of the international search report**

28 July 2004

**Name and mailing address of the ISA/US**

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer
Roxiang Li

Telephone No. (571) 272-1600

Form PCT/ISA/210 (second sheet) (July 1998)
BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-7, drawn to a method for identifying a compound that inhibits NF-kB-dependent transcription or p38-dependent transcription by determining whether the test compound inhibits the association of a Pellino-1 polypeptide (SEQ ID NO: 4 or its fragments) with its binding partner.

Group II, claims 8-16, drawn to an inhibitory nucleic acid that binds to a nucleic acid encoding SEQ ID NO: 4 or its fragments.

Group III, claims 17-21, drawn to an inhibitory polypeptide comprising an antibody fragment that binds to a polypeptide comprising SEQ ID NO: 4 or its fragments.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is drawn to a method for identifying a compound that inhibits NF-kB-dependent transcription or p38-dependent transcription by determining whether the test compound inhibits the association of a Pellino-1 polypeptide (SEQ ID NO: 4 or its fragments) with its binding partner, whereas Group II and Group III are drawn to two different products, a nucleic acids and a polypeptide, which do not share a common structure. Group I is not related to group II or Group III as a product and a process of making or using. Each group appears to have its own special technical feature.

The special technical feature of Group I is considered to be a method for identifying a compound that inhibits NF-kB-dependent transcription or p38-dependent transcription by determining whether the test compound inhibits the association of a Pellino-1 polypeptide (SEQ ID NO: 4 or its fragments) with its binding partner.

The special technical feature of Group II is considered to be an inhibitory nucleic acid that binds to a nucleic acid encoding SEQ ID NO: 4 or its fragments.

The special technical feature of Group III is considered to be an inhibitory polypeptide comprising an antibody fragment that binds to a polypeptide comprising SEQ ID NO: 4 or its fragments, respectively.

Accordingly, Groups I-III are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept. Thus, unity of invention is lacking and restriction is appropriate.

In the absence of any response from the applicant, this authority will establish the International Search Report based on the main invention. The claims drawn to the main invention are as follows:

Claims 1-7.
### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7

**Remark on Protest**

☒ The additional search fees were accompanied by the applicant’s protest.

☐ No protest accompanied the payment of additional search fees.